Wall Street brokerages expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce sales of $930,000.00 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Esperion Therapeutics’ earnings, with the lowest sales estimate coming in at $900,000.00 and the highest estimate coming in at $1.00 million. The company is expected to issue its next quarterly earnings report on Thursday, November 7th.
On average, analysts expect that Esperion Therapeutics will report full-year sales of $147.95 million for the current financial year, with estimates ranging from $146.40 million to $149.00 million. For the next financial year, analysts forecast that the firm will post sales of $175.51 million, with estimates ranging from $115.34 million to $207.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($0.15). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.05 million. During the same quarter last year, the company posted ($1.71) earnings per share. The business’s revenue for the quarter was up 9720.0% compared to the same quarter last year.
In other news, CEO Timothy M. Mayleben bought 2,500 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were purchased at an average cost of $35.25 per share, with a total value of $88,125.00. Following the acquisition, the chief executive officer now directly owns 76,015 shares in the company, valued at $2,679,528.75. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Target N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was purchased at an average cost of $42.65 per share, for a total transaction of $2,132,500.00. Following the completion of the acquisition, the insider now owns 3,572,964 shares in the company, valued at $152,386,914.60. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 142,500 shares of company stock worth $5,291,825. 7.70% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Aperio Group LLC bought a new position in Esperion Therapeutics in the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. bought a new position in Esperion Therapeutics in the 2nd quarter valued at about $32,000. Royal Bank of Canada increased its holdings in Esperion Therapeutics by 38.1% in the 2nd quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 811 shares during the period. Swiss National Bank increased its holdings in Esperion Therapeutics by 2.0% in the 2nd quarter. Swiss National Bank now owns 44,900 shares of the biopharmaceutical company’s stock valued at $2,089,000 after buying an additional 900 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Esperion Therapeutics by 1.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 104,247 shares of the biopharmaceutical company’s stock valued at $4,850,000 after buying an additional 1,114 shares during the period.
NASDAQ:ESPR traded up $1.41 during mid-day trading on Friday, reaching $38.41. 51,863 shares of the company’s stock were exchanged, compared to its average volume of 360,493. Esperion Therapeutics has a one year low of $33.13 and a one year high of $60.99. The firm has a market capitalization of $994.72 million, a PE ratio of -5.09 and a beta of 1.89. The business’s fifty day simple moving average is $36.62 and its two-hundred day simple moving average is $42.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.65 and a current ratio of 5.65.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: How to build a Fibonacci channel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.